theory clinical_105_1
imports Main

begin

typedecl entity
typedecl event

consts
  Trastuzumab :: "entity ⇒ bool"
  HER2 :: "entity ⇒ bool"
  Mutation :: "entity ⇒ bool"
  Bind :: "event ⇒ bool"
  Agent :: "event ⇒ entity ⇒ bool"
  Patient :: "event ⇒ entity ⇒ bool"
  ExtracellularDomain :: "entity ⇒ bool"
  InhibitoryEffect :: "event ⇒ bool"
  IntracellularDomain :: "entity ⇒ bool"
  HER2V777L :: "entity ⇒ bool"
  TyrosineKinaseDomain :: "entity ⇒ bool"
  LocatedIn :: "entity ⇒ entity ⇒ bool"
  Resistance :: "entity ⇒ bool"
  AntibodyTherapy :: "entity ⇒ bool"
  Cause :: "event ⇒ bool"
  To :: "entity ⇒ entity ⇒ bool"
  Lead :: "event ⇒ bool"
  Target :: "event ⇒ bool"

(* Explanation 1: Because trastuzumab binds to the HER2 extracellular domain, it may have no inhibitory effect on the HER2-activating mutation in the intracellular kinase domain. *)
axiomatization where
  explanation_1: "∃x y z e1 e2. Trastuzumab x ∧ HER2 y ∧ Mutation z ∧ Bind e1 ∧ Agent e1 x ∧ Patient e1 y ∧ ExtracellularDomain y ∧ InhibitoryEffect e2 ∧ Agent e2 x ∧ Patient e2 z ∧ IntracellularDomain z"

(* Explanation 2: The HER2 V777L mutation is located in the tyrosine kinase domain. *)
axiomatization where
  explanation_2: "∃x y. HER2V777L x ∧ Mutation x ∧ TyrosineKinaseDomain y ∧ LocatedIn x y"

(* Explanation 3: HER2 V777L may cause resistance to antibody therapy. *)
axiomatization where
  explanation_3: "∃x y z e. HER2V777L x ∧ Resistance y ∧ AntibodyTherapy z ∧ Cause e ∧ Agent e x ∧ Patient e y ∧ To y z"

(* Explanation 4: The location of the HER2 V777L mutation in the tyrosine kinase domain can lead to resistance to trastuzumab, as trastuzumab targets the extracellular domain. *)
axiomatization where
  explanation_4: "∃x y z w e1 e2. HER2V777L x ∧ Mutation x ∧ TyrosineKinaseDomain y ∧ Resistance z ∧ Trastuzumab w ∧ Lead e1 ∧ Agent e1 x ∧ Patient e1 z ∧ To z w ∧ Target e2 ∧ Agent e2 w ∧ Patient e2 y ∧ ExtracellularDomain y"

theorem hypothesis:
  assumes asm: "HER2V777L x ∧ Trastuzumab z"
  (* Hypothesis: HER2 V777L may cause resistance to trastuzumab, as trastuzumab binds to the extracellular kinase domain, whereas the mutation is in the intracellular kinase domain *)
  shows "∃x y z e1 e2. HER2V777L x ∧ Resistance y ∧ Trastuzumab z ∧ Cause e1 ∧ Agent e1 x ∧ Patient e1 y ∧ To y z ∧ Bind e2 ∧ Agent e2 z ∧ Patient e2 x ∧ ExtracellularDomain x ∧ IntracellularDomain x"
proof -
  (* From the known information, we have HER2V777L x and Trastuzumab z. *)
  from asm have "HER2V777L x ∧ Trastuzumab z" by blast
  
  (* Explanation 2 provides that HER2 V777L mutation is located in the tyrosine kinase domain. *)
  (* This corresponds to logical proposition C. *)
  from explanation_2 have "∃y. HER2V777L x ∧ TyrosineKinaseDomain y ∧ LocatedIn x y" sledgehammer
  
  (* Explanation 4 states that the location of the HER2 V777L mutation in the tyrosine kinase domain leads to resistance to trastuzumab, as trastuzumab targets the extracellular domain. *)
  (* This corresponds to logical proposition E and F. *)
  from explanation_4 have "∃y z w e1 e2. HER2V777L x ∧ TyrosineKinaseDomain y ∧ Resistance z ∧ Trastuzumab w ∧ Lead e1 ∧ Agent e1 x ∧ Patient e1 z ∧ To z w ∧ Target e2 ∧ Agent e2 w ∧ Patient e2 y ∧ ExtracellularDomain y" <ATP>
  
  (* Using the logical relation Implies(And(C, F), E), we can infer that the location of the HER2 V777L mutation in the tyrosine kinase domain leads to resistance to trastuzumab. *)
  (* Therefore, we can conclude that HER2 V777L may cause resistance to trastuzumab. *)
  then have "∃y z e1 e2. Resistance y ∧ Trastuzumab z ∧ Cause e1 ∧ Agent e1 x ∧ Patient e1 y ∧ To y z ∧ Bind e2 ∧ Agent e2 z ∧ Patient e2 x ∧ ExtracellularDomain x ∧ IntracellularDomain x" <ATP>
  
  then show ?thesis <ATP>
qed

end
